Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Qiagen lifts annual forecast as COVID testing boosts third-quarter profit

Published 11/03/2021, 04:18 PM
Updated 11/03/2021, 04:51 PM
© Reuters. A logo of a testing company Qiagen is seen as Economy Minister Andreas Pinkwart and Health Minister Karl-Josef Laumann of the German state Northrhine Westphalia visit Qiagen's facility, in Hilden, Germany, September 8, 2020. REUTERS/Leon Kuegeler

© Reuters. A logo of a testing company Qiagen is seen as Economy Minister Andreas Pinkwart and Health Minister Karl-Josef Laumann of the German state Northrhine Westphalia visit Qiagen's facility, in Hilden, Germany, September 8, 2020. REUTERS/Leon Kuegeler

(Reuters) -Qiagen on Wednesday raised its full-year forecasts for profit and revenue, with higher demand for its non-coronavirus products as well COVID-19 tests helping the U.S.-German genetic testing specialist beat quarterly profit expectations.

The company's products include several types of ultra-rapid, portable and antigen-based coronavirus tests that have brought in millions in sales since the beginning of the pandemic.

The company said its non-COVID related products grew 17% in the third quarter, at constant exchange rates, boosted by higher demand for tuberculosis testing, which brought in $79 million.

Chief Executive Thierry Bernard said the company was on track to achieve its 2021 sales target and would cross more than $2 billion in net sales.

© Reuters. A logo of a testing company Qiagen is seen as Economy Minister Andreas Pinkwart and Health Minister Karl-Josef Laumann of the German state Northrhine Westphalia visit Qiagen's facility, in Hilden, Germany, September 8, 2020. REUTERS/Leon Kuegeler

Qiagen (NYSE:QGEN) said its annual revenue will grow 15% compared to the prior forecast of 12% growth. It forecast adjusted diluted earnings per share of $2.48, from prior guidance of $2.42.

Qiagen said third-quarter adjusted earnings per share rose to $0.58 on a currency-adjusted basis, beating the $0.54 expected on average by analysts.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.